Double maintains 1 strategies that include EDIT - Editas Medicine, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GSY | -0.03% | $2.73B | 0.22% |
BSMW | 0.04% | $107.26M | 0.18% |
VGLT | 0.05% | $9.82B | 0.04% |
TLH | 0.07% | $11.46B | 0.15% |
GOVT | -0.07% | $27.51B | 0.05% |
WIP | -0.08% | $382.80M | 0.5% |
SCHQ | 0.09% | $756.36M | 0.03% |
CANE | -0.13% | $10.44M | 0.29% |
FLIA | 0.17% | $686.39M | 0.25% |
MLN | -0.18% | $540.30M | 0.24% |
AGGH | -0.19% | $323.99M | 0.29% |
LMBS | -0.24% | $5.11B | 0.64% |
TIPX | 0.30% | $1.67B | 0.15% |
JBND | -0.31% | $2.31B | 0.25% |
CGCB | -0.32% | $2.47B | 0.27% |
BNO | -0.37% | $103.68M | 1% |
SPTL | 0.42% | $11.61B | 0.03% |
USO | 0.49% | $1.18B | 0.6% |
AGZ | -0.51% | $614.02M | 0.2% |
GBIL | -0.56% | $6.38B | 0.12% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 48.93% | $44.43M | 0.5% |
ARKG | 48.22% | $1.05B | 0.75% |
XBI | 44.45% | $4.95B | 0.35% |
PTH | 43.84% | $101.07M | 0.6% |
IBB | 42.80% | $5.36B | 0.45% |
IWC | 40.28% | $824.65M | 0.6% |
IWO | 39.39% | $11.48B | 0.24% |
BBH | 39.08% | $329.82M | 0.35% |
PRNT | 38.72% | $76.61M | 0.66% |
PINK | 38.70% | $133.06M | 0.5% |
FBT | 38.30% | $1.01B | 0.54% |
IWM | 38.24% | $64.00B | 0.19% |
QQQJ | 38.09% | $617.03M | 0.15% |
VTWO | 38.09% | $13.29B | 0.07% |
PBE | 37.77% | $223.24M | 0.58% |
KJUL | 37.67% | $120.75M | 0.79% |
NUSC | 37.63% | $1.13B | 0.31% |
ISCG | 37.61% | $679.06M | 0.06% |
GSSC | 37.39% | $586.95M | 0.2% |
KJAN | 37.31% | $289.38M | 0.79% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SUPN | -21.10% | $1.74B | +16.49% | 0.00% |
PRG | -17.65% | $1.20B | -14.53% | 1.68% |
CNK | -17.54% | $3.46B | +39.22% | 0.53% |
XOS | -13.09% | $25.10M | -56.30% | 0.00% |
NOC | -12.04% | $71.10B | +13.32% | 1.72% |
SAND | -11.09% | $2.65B | +65.99% | 0.63% |
BMBL | -8.63% | $666.23M | -38.63% | 0.00% |
SBLK | -8.30% | $2.01B | -29.78% | 8.44% |
MO | -7.70% | $98.96B | +28.98% | 6.98% |
LITB | -6.13% | $21.70M | -78.27% | 0.00% |
NEUE | -6.00% | $61.96M | +27.57% | 0.00% |
PM | -5.90% | $281.78B | +78.65% | 3.00% |
HUSA | -5.63% | $22.94M | -6.82% | 0.00% |
K | -5.54% | $27.41B | +36.96% | 2.88% |
ED | -5.48% | $35.36B | +9.76% | 3.39% |
AXON | -5.45% | $63.73B | +178.21% | 0.00% |
TEF | -5.36% | $29.29B | +23.28% | 6.30% |
PHG | -5.07% | $22.88B | -4.21% | 4.03% |
PSN | -4.90% | $7.54B | -13.74% | 0.00% |
CPSH | -4.60% | $40.67M | +64.71% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -29.79% | $296.79M | 1.43% |
TAIL | -26.05% | $99.76M | 0.59% |
VIXY | -25.96% | $165.69M | 0.85% |
TPMN | -13.62% | $30.81M | 0.65% |
IVOL | -12.00% | $349.27M | 1.02% |
XONE | -11.19% | $585.86M | 0.03% |
BSMR | -10.52% | $255.58M | 0.18% |
IBTG | -10.33% | $1.92B | 0.07% |
CLIP | -10.17% | $1.52B | 0.07% |
SPTS | -9.47% | $5.78B | 0.03% |
USTB | -8.97% | $1.29B | 0.35% |
TFLO | -7.98% | $6.83B | 0.15% |
SCHO | -7.78% | $11.46B | 0.03% |
FTSD | -7.66% | $231.79M | 0.25% |
CARY | -7.33% | $347.36M | 0.8% |
WEAT | -7.22% | $117.15M | 0.28% |
VGSH | -7.03% | $22.80B | 0.03% |
FXY | -6.96% | $815.67M | 0.4% |
STOT | -6.88% | $253.88M | 0.45% |
KRBN | -6.82% | $162.36M | 0.85% |
Finnhub
Editas Medicine, Inc. added to Russell 3000E Index...
Finnhub
Editas Medicine, Inc. added to Russell Microcap Index...
Finnhub
Editas Medicine, Inc. added to Russell Microcap Value Index...
Finnhub
Editas Medicine, Inc. added to Russell 3000E Value Index...
Yahoo
Editas Medicine stock has more than doubled over the past few months, but it's still way down from its previous peak. It looks like the company could have a successful new delivery system for its next-generation treatment candidates. The average Wall Street analyst following Editas Medicine (NASDAQ: EDIT) thinks the gene therapy stock can reach $3.25 per share in the next year.
Yahoo
Sarepta Therapeutics is facing severe safety problems with its most important medicine. Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Let's consider why investors should stay a safe distance away from these two biotech companies.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
APPN | 50.33% | $2.15B | -6.03% | 0.00% |
CRSP | 49.92% | $4.10B | -12.07% | 0.00% |
ANDE | 48.63% | $1.24B | -27.14% | 2.12% |
NTLA | 47.26% | $990.25M | -57.28% | 0.00% |
COMP | 46.33% | $3.41B | +78.06% | 0.00% |
KRYS | 46.14% | $4.01B | -24.37% | 0.00% |
RBA | 44.94% | $19.57B | +38.36% | 1.09% |
ADEA | 44.32% | $1.54B | +26.69% | 1.40% |
ROCK | 44.08% | $1.79B | -11.41% | 0.00% |
ABCL | 43.64% | $1.08B | +21.96% | 0.00% |
RXRX | 43.63% | $2.04B | -32.93% | 0.00% |
MVIS | 43.27% | $284.16M | +7.55% | 0.00% |
FATE | 42.73% | $119.22M | -68.29% | 0.00% |
ADI | 42.15% | $117.59B | +3.81% | 1.61% |
GRMN | 40.77% | $40.12B | +27.89% | 1.52% |
DNLI | 40.74% | $2.05B | -39.28% | 0.00% |
BEAM | 40.60% | $1.69B | -28.30% | 0.00% |
ALEC | 40.34% | $147.99M | -67.40% | 0.00% |
APG | 39.77% | $14.29B | +35.18% | 0.00% |
ALLO | 39.06% | $258.10M | -49.36% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AEP | -0.01% | $54.73B | +16.78% | 3.58% |
FE | -0.12% | $23.03B | +4.26% | 4.32% |
PARAA | -0.12% | $15.17B | +22.42% | 0.89% |
PRA | 0.20% | $1.17B | +86.82% | 0.00% |
HLF | 0.27% | $889.12M | -15.98% | 0.00% |
UUU | -0.28% | $6.64M | +78.38% | 0.00% |
AWK | -0.30% | $26.90B | +6.78% | 2.27% |
FATBB | 0.32% | $45.45M | -14.20% | 11.38% |
STNG | -0.39% | $2.06B | -50.30% | 4.00% |
CNR | 0.39% | $3.57B | -33.51% | 1.08% |
DRD | -0.40% | $1.12B | +50.52% | 2.12% |
CE | -0.44% | $6.21B | -57.91% | 2.58% |
DOGZ | 0.48% | $363.33M | +65.16% | 0.00% |
DFIN | -0.49% | $1.70B | +3.14% | 0.00% |
VTMX | 0.53% | $2.41B | -9.04% | 2.77% |
CAG | -0.57% | $9.74B | -28.22% | 6.87% |
FSM | -0.69% | $1.95B | +30.06% | 0.00% |
FOUR | -0.79% | $6.76B | +33.91% | 0.00% |
GORV | -0.84% | $25.03M | -91.07% | 0.00% |
SO | -0.86% | $99.90B | +17.18% | 3.20% |
Current Value
$2.281 Year Return
Current Value
$2.281 Year Return